Dabigatran etexilate Zentiva: Uses, Dosage & Side Effects
Direct oral anticoagulant (DOAC) – direct thrombin inhibitor for stroke prevention and blood clot treatment
Quick facts about Dabigatran etexilate Zentiva
Key Takeaways
- Dabigatran etexilate Zentiva is a bioequivalent generic of Pradaxa, containing the same active substance at the same doses, approved to the same quality standards by the European Medicines Agency.
- Dabigatran is a direct thrombin inhibitor (DTI) – the only DOAC that targets thrombin (factor IIa) rather than factor Xa, giving it a unique pharmacological profile among oral anticoagulants.
- The RE-LY trial demonstrated that dabigatran 150 mg twice daily was superior to warfarin for stroke prevention in atrial fibrillation, while the 110 mg dose showed similar efficacy with significantly lower bleeding rates.
- Idarucizumab (Praxbind) is a specific, purpose-built reversal agent that completely neutralises the anticoagulant effect of dabigatran within minutes – a unique advantage among DOACs.
- Renal function must be assessed before starting treatment and monitored regularly, as approximately 80% of dabigatran is excreted unchanged via the kidneys.
What Is Dabigatran etexilate Zentiva and What Is It Used For?
Quick Answer: Dabigatran etexilate Zentiva is a generic direct oral anticoagulant (DOAC) that works by directly inhibiting thrombin (factor IIa). It is used to prevent stroke in atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and prevent blood clots after hip or knee replacement surgery.
Dabigatran etexilate Zentiva is a prescription anticoagulant medication that belongs to the class of direct oral anticoagulants (DOACs). It contains dabigatran etexilate, a prodrug that is rapidly converted to its active form, dabigatran, after oral administration. Dabigatran is a potent, competitive, reversible direct thrombin inhibitor. Thrombin (factor IIa) occupies a central and pivotal role in the coagulation cascade – it is the final enzyme responsible for converting fibrinogen to fibrin, the structural protein of blood clots. By directly and specifically blocking thrombin, dabigatran effectively prevents clot formation.
The original branded version of dabigatran etexilate, Pradaxa, was developed by Boehringer Ingelheim and was the first direct oral anticoagulant to receive regulatory approval. It was authorised by the European Medicines Agency (EMA) in 2008 for the prevention of venous thromboembolism after joint replacement surgery, and subsequently for stroke prevention in atrial fibrillation in 2011. Dabigatran etexilate Zentiva is a generic version manufactured by Zentiva, meeting the same rigorous quality, safety, and bioequivalence standards required by the EMA for all generic medicines.
Dabigatran holds a unique position among DOACs as it is the only agent in this class that inhibits thrombin directly. The other DOACs – apixaban, rivaroxaban, and edoxaban – all target factor Xa. This difference in mechanism of action gives dabigatran distinct pharmacological characteristics, including its amenability to haemodialysis (due to low protein binding of approximately 35%) and its specific reversibility with idarucizumab, a monoclonal antibody fragment designed to bind dabigatran with extremely high affinity.
Dabigatran etexilate itself is a prodrug with no pharmacological activity. After oral ingestion, it is rapidly absorbed from the gastrointestinal tract and converted to the active compound dabigatran by esterase-catalysed hydrolysis in plasma and the liver. The absolute bioavailability of the oral formulation is approximately 6.5%, which is relatively low but consistent, allowing for predictable dosing without routine coagulation monitoring. Peak plasma concentrations are typically achieved within 0.5 to 2 hours after administration.
Approved Indications
Dabigatran etexilate Zentiva is approved for the following clinical indications, consistent with the originator product (Pradaxa) across major regulatory agencies (EMA, FDA):
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) who have one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75, heart failure (NYHA Class ≥II), diabetes mellitus, or hypertension.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, following treatment with a parenteral anticoagulant administered for at least 5 days.
- Prevention of recurrent DVT and PE in adults who have been previously treated.
- Prevention of venous thromboembolism (VTE) in adult patients who have undergone elective hip or knee replacement surgery (primary VTE prevention).
The European Society of Cardiology (ESC) 2024 guidelines for the management of atrial fibrillation recommend DOACs, including dabigatran, as the preferred oral anticoagulants over vitamin K antagonists (warfarin) for stroke prevention in patients with non-valvular atrial fibrillation. DOACs are recommended with a Class I, Level A evidence rating, the strongest level of recommendation.
Mechanism of Action
Dabigatran is a potent, competitive, reversible direct inhibitor of thrombin (factor IIa). Unlike heparin and its derivatives, which act indirectly through antithrombin III, dabigatran binds directly to the active site of thrombin, blocking its enzymatic activity. This direct binding inhibits both free thrombin circulating in the blood and thrombin that is already bound to fibrin within existing clots (fibrin-bound thrombin). By inhibiting thrombin, dabigatran prevents the conversion of fibrinogen to fibrin, inhibits thrombin-induced platelet aggregation, and blocks thrombin-mediated activation of factors V, VIII, XI, and XIII. The net result is a comprehensive anticoagulant effect that reduces both the formation and extension of thrombi.
An important pharmacological feature of dabigatran is its reversibility. The binding of dabigatran to thrombin is competitive and reversible, meaning that as dabigatran is eliminated from the body, thrombin activity is gradually restored. Furthermore, the specific reversal agent idarucizumab (Praxbind) can immediately and completely reverse the anticoagulant effect of dabigatran by binding to it with approximately 350 times greater affinity than thrombin, effectively sequestering the drug and rendering it inactive within minutes.
What Should You Know Before Taking Dabigatran etexilate Zentiva?
Quick Answer: Before starting dabigatran, your doctor will assess your kidney function (creatinine clearance), bleeding risk, and other medications. Dabigatran is contraindicated in severe renal impairment (CrCl <30 mL/min), active clinically significant bleeding, and in patients with prosthetic heart valves. Renal function monitoring is essential throughout treatment.
Before your healthcare provider prescribes dabigatran etexilate Zentiva, a comprehensive assessment of your medical history, kidney function, bleeding risk, and concurrent medications will be performed. Because dabigatran is primarily excreted by the kidneys (approximately 80% as unchanged drug), renal function is the most important factor in determining whether dabigatran is appropriate and what dose should be used. This renal dependence distinguishes dabigatran from other DOACs such as apixaban and rivaroxaban, which have more balanced hepatic and renal elimination pathways.
Contraindications
Dabigatran etexilate Zentiva should not be used in the following situations:
- Severe renal impairment: Creatinine clearance (CrCl) below 30 mL/min. Due to the predominantly renal elimination of dabigatran, severe kidney impairment leads to dangerous drug accumulation and unacceptable bleeding risk. In the United States, the FDA permits use down to CrCl 15 mL/min at a reduced dose of 75 mg twice daily, but the EMA contraindication remains at CrCl <30 mL/min.
- Active clinically significant bleeding: Patients with ongoing haemorrhage from any site, including gastrointestinal, intracranial, or other clinically significant bleeding.
- Hypersensitivity: Known allergy to dabigatran etexilate, dabigatran, or any of the excipients in the capsule formulation.
- Lesions or conditions at significant risk of major bleeding: Including current or recent gastrointestinal ulceration, malignant neoplasms at high risk of bleeding, recent brain or spinal injury or surgery, oesophageal varices, arteriovenous malformations, vascular aneurysms, or major intraspinal or intracerebral vascular abnormalities.
- Concomitant treatment with systemic ketoconazole, cyclosporine, itraconazole, dronedarone, and glecaprevir/pibrentasvir: These drugs are strong P-glycoprotein (P-gp) inhibitors that significantly increase dabigatran plasma levels, raising the risk of bleeding to unacceptable levels.
- Hepatic impairment or liver disease expected to have any impact on survival: Although dabigatran is not extensively metabolised by the liver, significant hepatic impairment may affect the esterase conversion of the prodrug.
- Prosthetic heart valves requiring anticoagulant treatment: The RE-ALIGN trial demonstrated increased rates of thromboembolic and bleeding events in patients with mechanical heart valves treated with dabigatran compared with warfarin. Dabigatran is therefore contraindicated in this population, and warfarin remains the standard of care.
Renal function (creatinine clearance) must be assessed before starting dabigatran and should be re-assessed at least annually in all patients. In patients over 75 years of age or those with any degree of renal impairment, kidney function should be checked at least every 6 months. In clinical situations where renal function may decline (e.g. dehydration, hypovolaemia, concomitant use of nephrotoxic medications), additional monitoring is required. Failure to monitor renal function can lead to dangerous drug accumulation and increased bleeding risk.
Warnings and Precautions
Special caution is required when prescribing dabigatran etexilate Zentiva in the following clinical situations:
- Increased bleeding risk: All anticoagulants increase the risk of bleeding. Conditions that further elevate this risk include uncontrolled hypertension, active peptic ulcer disease, recent biopsy or major trauma, bacterial endocarditis, thrombocytopenia, or congenital/acquired bleeding disorders. Concurrent use of antiplatelet agents (aspirin, clopidogrel), NSAIDs, or other anticoagulants significantly increases the risk of haemorrhage.
- Moderate renal impairment (CrCl 30–50 mL/min): A dose reduction to 110 mg twice daily is recommended for patients with atrial fibrillation who have moderate renal impairment, as dabigatran exposure increases substantially with declining kidney function. Close monitoring is essential.
- Elderly patients (age ≥80): A dose of 110 mg twice daily is recommended in the EMA-approved prescribing information for patients aged 80 and above with atrial fibrillation, due to the higher bleeding risk in this population and the age-related decline in renal function.
- Low body weight (<50 kg): Limited clinical experience exists. Close clinical monitoring is recommended.
- Spinal or epidural anaesthesia: Patients receiving neuraxial anaesthesia or undergoing spinal/epidural puncture are at risk of epidural or spinal haematoma, which may cause long-term or permanent paralysis. Specific timing guidelines must be followed – at least 24 hours should elapse after the last dose before catheter removal, and at least 2 hours after catheter removal before the next dose.
- Gastrointestinal effects: Dabigatran is associated with a higher rate of gastrointestinal bleeding compared with warfarin and some other DOACs. The drug contains tartaric acid in its capsule formulation, which lowers the local pH to enhance absorption, but may contribute to dyspepsia and gastrointestinal discomfort in some patients. Taking dabigatran with food or a glass of water may help reduce these symptoms.
- Surgery and invasive procedures: Dabigatran must be discontinued before elective surgery. The recommended discontinuation period depends on kidney function and the bleeding risk of the procedure (typically 24–96 hours before surgery). Your surgeon and anaesthesiologist should be aware that you are taking dabigatran.
Pregnancy and Breastfeeding
There are limited data on the use of dabigatran etexilate during pregnancy. Animal reproductive toxicity studies have shown adverse effects on fertility and embryo-foetal development at maternally toxic doses. As a precautionary measure, dabigatran etexilate should not be used during pregnancy unless clearly necessary and the potential benefit justifies the potential risk to the foetus. Women of childbearing potential should discuss effective contraception with their doctor whilst taking this medication.
It is not known whether dabigatran is excreted in human breast milk. No clinical data are available on the use of dabigatran during breastfeeding. As a precautionary measure, breastfeeding should be discontinued during treatment with dabigatran etexilate. Your doctor will help you weigh the benefits of breastfeeding against the benefits of continuing anticoagulation therapy.
Dabigatran etexilate capsules must be swallowed whole with water. They must not be opened, crushed, or chewed. Opening the capsules increases the bioavailability by approximately 75%, which raises the bleeding risk to unacceptable levels. If you have difficulty swallowing capsules, speak with your prescriber about alternative anticoagulant options rather than attempting to alter the capsule formulation.
How Does Dabigatran etexilate Zentiva Interact with Other Drugs?
Quick Answer: Dabigatran is transported by P-glycoprotein (P-gp), so drugs that inhibit or induce P-gp can significantly alter dabigatran levels. Strong P-gp inhibitors (ketoconazole, dronedarone, cyclosporine) are contraindicated. P-gp inducers (rifampicin, St John’s Wort) significantly reduce dabigatran levels and should be avoided. Concomitant use of antiplatelet agents, NSAIDs, and other anticoagulants increases bleeding risk.
Understanding drug interactions is critical for the safe use of dabigatran etexilate. Unlike many other medications, dabigatran is not significantly metabolised by the cytochrome P450 (CYP) enzyme system, which means it has fewer metabolic interactions than drugs such as warfarin. However, dabigatran etexilate is a substrate of the efflux transporter P-glycoprotein (P-gp), and interactions involving P-gp are clinically significant and can be dangerous. P-gp acts as a gatekeeper in the intestinal wall, limiting the absorption of dabigatran. When P-gp is inhibited, more dabigatran is absorbed, leading to higher plasma levels and increased bleeding risk; when P-gp is induced, less drug is absorbed, resulting in subtherapeutic levels and increased thrombotic risk.
Major Interactions (Contraindicated or Avoid)
| Drug | Mechanism | Effect | Action |
|---|---|---|---|
| Ketoconazole (systemic) | Strong P-gp inhibitor | Increases dabigatran levels by up to 150% | Contraindicated |
| Dronedarone | Strong P-gp inhibitor | Increases dabigatran levels by ~70% | Contraindicated |
| Itraconazole (systemic) | Strong P-gp inhibitor | Significantly increases dabigatran levels | Contraindicated |
| Cyclosporine | Strong P-gp inhibitor | Significantly increases dabigatran levels | Contraindicated |
| Rifampicin | Strong P-gp inducer | Reduces dabigatran levels by ~66% | Avoid – risk of treatment failure |
| St John’s Wort | P-gp inducer | Significantly reduces dabigatran levels | Avoid – risk of treatment failure |
| Carbamazepine, Phenytoin | P-gp inducers | Expected to reduce dabigatran levels | Avoid – expected reduction in efficacy |
Moderate Interactions (Use with Caution)
| Drug | Mechanism | Effect | Action |
|---|---|---|---|
| Amiodarone | Moderate P-gp inhibitor | Increases dabigatran levels by ~60% | No dose adjustment for AF; consider 150 mg BID for VTE prevention |
| Verapamil | Moderate P-gp inhibitor | Increases dabigatran levels by 12–180% depending on timing | Take dabigatran ≥2 hours before verapamil; dose reduction may be needed |
| Aspirin | Antiplatelet effect | Additive increase in bleeding risk | Use with caution; assess risk-benefit carefully |
| Clopidogrel, Ticagrelor | Antiplatelet effect | Significantly increased bleeding risk | Use only when clearly indicated; minimise duration of combination therapy |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Antiplatelet + GI mucosal damage | Increased bleeding risk, especially GI | Avoid long-term use; use lowest effective dose for shortest duration |
| SSRIs/SNRIs | Impaired platelet function | Modestly increased bleeding risk | Monitor for signs of bleeding |
It is essential to inform your doctor and pharmacist about all medications you are taking, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins. The interaction between dabigatran and P-gp modulators is time-dependent – for example, the interaction with verapamil is most pronounced when both drugs are taken simultaneously, but can be minimised by taking dabigatran at least 2 hours before verapamil.
Proton pump inhibitors (such as omeprazole, esomeprazole, and pantoprazole) reduce the absorption of dabigatran by approximately 20–30% by raising gastric pH. However, clinical trials (including RE-LY) did not show a significant impact on clinical outcomes in patients taking PPIs concurrently with dabigatran. PPIs may actually be beneficial in reducing the gastrointestinal side effects associated with dabigatran’s tartaric acid component, and no dose adjustment is required.
What Is the Correct Dosage of Dabigatran etexilate Zentiva?
Quick Answer: The standard dose for stroke prevention in atrial fibrillation is 150 mg twice daily, with a reduced dose of 110 mg twice daily for patients aged ≥80 years or those at higher bleeding risk. For VTE prevention after joint surgery, the dose is 220 mg once daily (or 150 mg once daily for patients ≥75 years or with CrCl 30–50 mL/min). All capsules must be swallowed whole – never opened or crushed.
The dosing of dabigatran etexilate varies depending on the clinical indication, patient age, renal function, and concomitant medications. It is critical that the correct dose is used for each indication, as under-dosing increases thrombotic risk while over-dosing increases bleeding risk. The capsules are available in three strengths: 75 mg, 110 mg, and 150 mg. All doses must be taken as whole capsules with a full glass of water, with or without food.
Adults – Atrial Fibrillation (Stroke Prevention)
Standard Dose
150 mg twice daily (one 150 mg capsule in the morning and one in the evening, approximately 12 hours apart). This is the recommended dose for most adults under 80 years of age with adequate renal function (CrCl ≥50 mL/min).
Reduced Dose
110 mg twice daily (one 110 mg capsule in the morning and one in the evening). This dose is recommended for:
- Patients aged 80 years and above
- Patients receiving concomitant verapamil (take dabigatran at the same time as verapamil)
- Patients at increased risk of bleeding (e.g. gastritis, oesophagitis, gastro-oesophageal reflux)
- Patients aged 75–80 years where the treating physician assesses that individual bleeding risk exceeds the thromboembolic risk
- Patients with moderate renal impairment (CrCl 30–50 mL/min) where assessed as being at higher risk of bleeding
Adults – Treatment of DVT and PE
DVT/PE Treatment
150 mg twice daily following treatment with a parenteral anticoagulant (such as low-molecular-weight heparin or unfractionated heparin) for at least 5 days. The parenteral anticoagulant provides immediate anticoagulation during the initial acute phase, after which oral therapy with dabigatran is continued.
A dose of 110 mg twice daily may be selected for patients aged ≥80 years or those receiving concomitant verapamil.
Adults – VTE Prevention After Joint Surgery
Hip Replacement Surgery
220 mg once daily (two 110 mg capsules taken together) for 28–35 days. Start with a single 110 mg capsule 1–4 hours after surgery (once haemostasis is established), then 220 mg once daily from the following day.
Reduced dose: 150 mg once daily (two 75 mg capsules) for patients aged ≥75 years, those with moderate renal impairment (CrCl 30–50 mL/min), or those receiving concomitant verapamil.
Knee Replacement Surgery
220 mg once daily (two 110 mg capsules taken together) for 10 days. Same initiation protocol as hip replacement. Reduced dose: 150 mg once daily for the same patient groups as above.
Children
Dabigatran etexilate is not recommended for use in children under 18 years of age for most indications due to insufficient data on safety and efficacy. However, paediatric formulations and dosing regimens have been studied in clinical trials for the treatment and prevention of venous thromboembolism in children. The EMA has approved a paediatric indication for the treatment of VTE and prevention of recurrent VTE in children from birth onwards, with dosing based on age and body weight using specific oral pellet and oral solution formulations. Consult the specialist prescribing information for detailed paediatric dosing.
Elderly
Elderly patients are at increased risk of both bleeding and thrombotic events. The EMA recommends a dose of 110 mg twice daily for patients aged 80 years and above with atrial fibrillation. For patients aged 75–80, the prescriber should assess the individual bleeding versus thromboembolic risk to decide between 150 mg and 110 mg twice daily. Renal function declines with age and must be monitored at least every 6 months in patients over 75.
Missed Dose
If you miss a dose of dabigatran etexilate, take it as soon as you remember, provided there are still at least 6 hours before the next scheduled dose. If less than 6 hours remain before your next dose, skip the missed dose and take the next capsule at the usual time. Do not take a double dose to compensate for a missed one. Missing doses of dabigatran increases the risk of blood clots, so try to maintain a consistent dosing schedule.
Overdose
Overdose of dabigatran etexilate may lead to haemorrhagic complications. There is no general antidote to reverse the pharmacological effect, but the specific reversal agent idarucizumab (Praxbind) is approved for the rapid and complete reversal of dabigatran’s anticoagulant effect in emergency situations. In an overdose scenario:
- Administer idarucizumab 5 g intravenously if available
- Consider oral activated charcoal if the overdose occurred within the preceding 1–2 hours
- Dabigatran can be removed by haemodialysis (approximately 35% protein bound), although clinical experience with this approach is limited
- Supportive care including fluid resuscitation, blood transfusion, and surgical haemostasis as appropriate
- Prothrombin complex concentrates (PCCs) may be considered if idarucizumab is unavailable, although evidence is limited
What Are the Side Effects of Dabigatran etexilate Zentiva?
Quick Answer: The most common side effects of dabigatran are gastrointestinal symptoms (dyspepsia, nausea, abdominal pain) and bleeding from various sites. Gastrointestinal bleeding is more common with dabigatran than with warfarin, while intracranial haemorrhage is significantly less common. Seek immediate medical attention for signs of serious bleeding.
Like all anticoagulants, the primary risk associated with dabigatran etexilate is bleeding. The RE-LY trial – the landmark study comparing dabigatran with warfarin in over 18,000 patients with atrial fibrillation – established a comprehensive safety profile that has been further refined through more than a decade of post-marketing surveillance and real-world evidence. Understanding the frequency and nature of side effects allows patients and prescribers to make informed decisions and recognise problems early.
A distinctive aspect of dabigatran’s side effect profile is the higher incidence of gastrointestinal symptoms compared with other DOACs and warfarin. This is believed to be related to the tartaric acid pellets within the capsule formulation, which create a local acidic environment to enhance absorption. These symptoms are generally mild to moderate and often improve over time or can be managed by taking the capsules with food or co-prescribing a proton pump inhibitor.
Common (affects 1–10 in 100 people)
Reported in 1–10% of patients in clinical trials
- Gastrointestinal haemorrhage (bleeding from stomach or intestines)
- Abdominal pain or discomfort
- Dyspepsia (indigestion)
- Nausea
- Diarrhoea
- Nosebleeds (epistaxis)
- Urogenital bleeding (blood in urine)
- Decreased haemoglobin levels
- Skin bruising or bleeding
- Wound secretion or bleeding after procedures
Uncommon (affects 1–10 in 1,000 people)
Reported in 0.1–1% of patients in clinical trials
- Decreased platelet count (thrombocytopenia)
- Allergic reactions (rash, pruritus, urticaria)
- Intracranial haemorrhage (bleeding in or around the brain)
- Haemoptysis (coughing up blood)
- Rectal bleeding
- Haemorrhoidal haemorrhage
- Gastric or oesophageal ulceration
- Gastro-oesophageal reflux disease
- Dysphagia (difficulty swallowing)
- Hepatic function abnormalities (elevated liver enzymes)
- Haemarthrosis (bleeding into joints)
- Traumatic haemorrhage or haematoma
Rare (affects 1–10 in 10,000 people)
Reported in 0.01–0.1% of patients in clinical trials
- Anaphylactic reaction (severe allergic reaction)
- Angioedema (swelling of face, lips, tongue or throat)
- Hepatic impairment or hepatitis
- Retroperitoneal haemorrhage (bleeding behind the abdominal cavity)
- Muscle haemorrhage
- Injection site or wound haematoma
Very Rare / Not Known
Reported in <0.01% of patients or frequency cannot be estimated from available data
- Bronchospasm
- Alopecia (hair loss)
- Oesophageal ulcer
Contact your doctor or go to the nearest emergency department immediately if you experience any of the following:
- Prolonged or unexplained bleeding from any site
- Black or tarry stools, or blood in stools
- Vomiting blood or material that looks like coffee grounds
- Pink or brown urine
- Sudden severe headache, confusion, vision changes, or weakness on one side (signs of intracranial bleeding)
- Signs of allergic reaction: swelling of face, lips, tongue or throat, difficulty breathing, severe skin rash
- Coughing up blood or blood-tinged sputum
The RE-LY trial demonstrated that dabigatran 150 mg twice daily had a major bleeding rate similar to warfarin but with a significantly lower rate of intracranial haemorrhage (0.30% vs. 0.74% per year, a 59% relative reduction). The 110 mg dose showed significantly lower rates of both major bleeding and intracranial haemorrhage compared with warfarin, while maintaining similar efficacy for stroke prevention. However, both doses of dabigatran were associated with a higher rate of gastrointestinal bleeding compared with warfarin, particularly in patients over 75 years of age. Real-world data from registries and post-marketing studies have largely confirmed the safety profile observed in the RE-LY trial.
How Should You Store Dabigatran etexilate Zentiva?
Quick Answer: Store dabigatran capsules in the original packaging to protect from moisture. Do not store above 30°C. Keep the bottle tightly closed or use blister packs. Once a bottle is opened, capsules must be used within 4 months. Keep out of reach of children.
Proper storage of dabigatran etexilate capsules is particularly important because the formulation is sensitive to moisture. The capsules contain tartaric acid pellets that are hygroscopic (moisture-attracting), and exposure to excessive moisture can compromise the integrity and efficacy of the medication. Following these storage guidelines ensures that your medication remains effective throughout its shelf life:
- Temperature: Store at room temperature, not exceeding 30°C (86°F). Do not refrigerate or freeze.
- Moisture: This is the most critical storage consideration. Store in the original packaging (blister pack or bottle with desiccant cap) to protect from moisture. Do not transfer capsules to daily pill organisers or other containers, as this can expose them to ambient humidity.
- Blister packs: Peel off only one blister at a time to take your dose. Do not push capsules through the foil.
- Bottles: Once opened, use within 4 months. Keep the bottle tightly closed after each use. The cap contains a desiccant – do not remove it.
- Children: Keep all medicines out of the sight and reach of children. Consider using a locked medicine cabinet.
- Expiry: Do not use after the expiry date stated on the packaging. The expiry date refers to the last day of that month.
- Disposal: Do not dispose of medicines via household waste or wastewater. Return unused medicines to your pharmacist for safe disposal.
If you notice any change in the appearance of the capsules (discolouration, damage, sticking together), do not take them and consult your pharmacist. Damaged or moisture-affected capsules may deliver an incorrect dose of medication.
What Does Dabigatran etexilate Zentiva Contain?
Quick Answer: Each capsule contains either 75 mg, 110 mg, or 150 mg of dabigatran etexilate (as dabigatran etexilate mesilate). The capsules also contain tartaric acid (to aid absorption), as well as excipients in the capsule shell including hypromellose, carrageenan, and potassium chloride.
Understanding the composition of your medication helps identify potential allergens or excipients that may cause sensitivity. The composition of dabigatran etexilate Zentiva capsules is designed to optimise the absorption and stability of the active ingredient.
Active Ingredient
- Dabigatran etexilate Zentiva 75 mg: Each hard capsule contains 75 mg of dabigatran etexilate (as dabigatran etexilate mesilate).
- Dabigatran etexilate Zentiva 110 mg: Each hard capsule contains 110 mg of dabigatran etexilate (as dabigatran etexilate mesilate).
- Dabigatran etexilate Zentiva 150 mg: Each hard capsule contains 150 mg of dabigatran etexilate (as dabigatran etexilate mesilate).
Excipients (Inactive Ingredients)
The following excipients are typically present in dabigatran etexilate capsule formulations:
- Capsule contents: Tartaric acid, acacia, hypromellose, dimethicone, talc, hydroxypropylcellulose.
- Capsule shell: Hypromellose, carrageenan, potassium chloride, titanium dioxide (E171), iron oxide yellow (E172), and may contain additional iron oxide colourants depending on strength.
- Printing ink: Shellac, iron oxide black (E172), potassium hydroxide.
Tartaric acid is a key excipient in dabigatran etexilate capsules. It creates a local acidic microenvironment in the stomach that enhances the dissolution and absorption of dabigatran etexilate, which has pH-dependent solubility. Without this acidic environment, the bioavailability of the drug would be even lower than the already modest 6.5%. This is why capsules must not be opened – disrupting the tartaric acid core alters the absorption profile significantly. It also explains why proton pump inhibitors, which raise gastric pH, modestly reduce dabigatran absorption.
Capsule Appearance
- 75 mg capsules: Hard capsules with a printed body and cap in a specific colour combination depending on the manufacturer. Consult your product packaging for the exact description.
- 110 mg capsules: Hard capsules, typically light blue cap and cream body (similar to originator appearance), printed with dosage information.
- 150 mg capsules: Hard capsules, typically light blue cap and cream body (similar to originator), printed with dosage information.
As a generic product, the exact appearance of Dabigatran etexilate Zentiva capsules may differ from the originator Pradaxa capsules in colour, markings, or size, but the active ingredient and its dose remain identical.
Frequently Asked Questions About Dabigatran etexilate Zentiva
References
This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY). N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa0905561
- Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER). N Engl J Med. 2009;361(24):2342–2352. doi:10.1056/NEJMoa0906598
- Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis (RE-VERSE AD). N Engl J Med. 2017;377(5):431–441. doi:10.1056/NEJMoa1707278
- Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement (RE-NOVATE II). Lancet. 2007;370(9591):949–956.
- Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves (RE-ALIGN). N Engl J Med. 2013;369(13):1206–1214. doi:10.1056/NEJMoa1300615
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi:10.1016/S0140-6736(13)62343-0
- European Society of Cardiology. 2024 ESC/EACTS Guidelines for the Management of Atrial Fibrillation. Eur Heart J. 2024. doi:10.1093/eurheartj/ehae176
- European Medicines Agency. Pradaxa (dabigatran etexilate) – Summary of Product Characteristics. EMA, 2024. EMA – Pradaxa
- U.S. Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate) – Prescribing Information. FDA, 2024.
- British National Formulary. Dabigatran etexilate. BNF, 2025. BNF – Dabigatran etexilate
- Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation. J Am Coll Cardiol. 2013;61(22):2264–2273.
- Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-world atrial fibrillation: meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost. 2016;116(4):754–763.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians specialising in clinical pharmacology, haematology, and internal medicine.
iMedic Medical Editorial Team – specialists in clinical pharmacology and anticoagulation therapy with extensive experience in evidence-based medical communication.
iMedic Medical Review Board – independent panel of medical experts who verify all content against current international guidelines (ESC, AHA/ACC, EMA, FDA, BNF, WHO).
All iMedic content follows the GRADE evidence framework and is based on Level 1A evidence (systematic reviews of randomised controlled trials) where available. We have no commercial funding or pharmaceutical sponsorship. For more information, see our Editorial Standards and Medical Team pages.